CORT Corcept Therapeutics Inc

$CORT Crazy triple-witching with 17M shares traded last Friday - $1.8B worth of the stock changed hands. With Relacorilant/CS' FDA approval and Lifyorli/PROC's EMA approval just around the corner, we should see $150 SP by year end. Then comes 2027 - Dazucorilant and Miricorilant rises from the horizon. We should see $250 to $300 SP by EOY 2027, or be acquired at such before then. GLTA and cheers!

$CORT looks like the Monarch ph2b mash study was completed 9/29. I wonder how long before we see top line data? Should be before next earnings report I hope.

$CORT With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of $150. More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above $200. Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all $B- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of $300. GL & cheers!

$CORT By year end, we should hear from FDA and EMA about Relacorilant for, respectively, CS and PROC. Approval for CS in US would double the Korlym/Relacorilant franchise's reveven to $2B annually, and approval for PROC in EU would more than double the cohorts of PROC from 200K to 400K, which similarly doubles the PROC franchise's revenue to$2B annually. The story does not end there, coming 2027 would bring about two more major franchasises for CORT, they are: Dazucorilant for ALS and Miricorilant for MASH. Dazucorilant has been proven and shown to significantly prolong the lives of ALS sufferers, and Miricorilant has shown more than effective to cure fatty liver, but perhaps too effective with adverse side effects. The current tritration study of Miricorilant is to find the optimal doage of Miricorilant for efficacy and suppressed l side effects. When these two franchasises are added, CORT's valuation will be skyrocketed to north of $300 with franchasises for CS, OC, ALS and MASH.

$CORT looks like that 10% of volume spike Friday at close was being added to the s&p 400 mid according to gemini. We might get some volatility Monday Tuesday due to others rebalancing.

$CORT Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) https://www.businesswire.com/news/home/20260918490790/en/Corcept-Announces-CHMP-Opinion-Recommending-EU-Marketing-Authorization-for-Lifyorli-Relacorilant The EC will review the CHMP's opinion and issue a final decision regarding approval in the fourth quarter of 2026.

$CORT Maduck retires. Did he do so because his 10b5-1 recently reached a set price (maybe 125) and cashed him out of 170k options or did his 10b5-1 have him exercise 170K options regardless of price in contemplation of retirement ?

$CORT to follow up on my below post I think it is somewhat significant that the CHMP version leaves out reference to Avastin as a search shows most do not use it as their first treatment. So leaving this out as a requirement that it must be tried first, moves number of patients Lifyori can be used in. Looks like most use Chemotherapy alone as a first line of treatment and EU may even restrict it as a first line use. Also doctors tend to hold it for a second remission.